By reverse transcriptase polymerase chain reaction on messenger RNA from human polymorphonuclear cells, we have isolated a sequence identical to the cDNA coding for intracellular interleukin 1 receptor antagonist (iclL-lra), but containing an additional in-frame 63-bp sequence located three codons downstream of the translation start of iclL-lra. This additional sequence is inserted between the first and second exon of the intracellular form, the latter of which is colinear with part of the first exon of the secreted form of IL-lra. The additional sequence is coded by an extra exon located 2 kb downstream the first iclL-lra-specific exon. The complementary DNA sequence of the alternatively spliced form of iclL-lra shows that the predicted protein differs from classical iclL-lra in the NH2 terminus by insertion of a leaderless sequence of 21 amino acids rich in glycine and glutamic acid residues. Transcripts coding for this new form of iclL-lra were detected in activated fibroblasts, keratinocytes, and at low levels in myelomonocytic cells. The recombinant protein expressed in COS cells had an apparent molecular mass in sodium dodecyl sulfate polyacrylamide gel electrophoresis of 25 kD compared to 22 kD of classical iclLlra, and was mostly intracellular. The ability of this new form of iclL-lra to inhibit IL-1 activity, in terms of induction of E-selectin and human immunodeficiency virus replication, was comparable to that of classical iclL-lra. We propose to refer to this new form of iclL-lra as iclL-lra type II.
I
L-lc~ and IL-1B are pleiotropic cytokines exerting a variety of effects on different tissues (1) . The potent inflammatory effects of IL-1 are under strict physiological control. IL-1 synthesis is inhibited by antiinflammatory cytokines, prostaglandins, and glucocorticoids (1) . IL-1 receptor type II (IL-1RII) is a nonsignaling, IL-l-binding molecule that acts as a regulated decoy target for IL-1 (2) (3) (4) . Finally, IL-1 is the only cytokine for which a polypeptide receptor antagonist (IL-lra) has been described (5-7). The existence of multiple levels of inhibition of IL-1 points to the necessity for a tight control of this mediator.
IL-lra is a polypeptide molecule that binds IL-1R type I (IL-1RI) and, less avidly, IL-1KII without any agonistic activity (8) . IL-lra is induced in different cell types, including mononuclear phagocytes, polymorphonuclear cells, and fibroblasts by IgG, cytokines, and bacterial products (8) . As an IL-1 competitor, IL-lra may represent a potentially useful pharmacological tool in inflammatory diseases (1) .
Two molecular forms of IL-lra have been identified and cloned. Secreted IL-lra (slL-lra) contains a classical 25-amino acid leader peptide giving a mature protein of 152 amino acids (6, 7) . Intracellular IL-lra (iclL-lra) has no leader sequence, thus predicting that this protein remains intraceUular (9) . slLlra and iclL-lra are generated from the same gene. iclL-lra transcripts originate from an alternative start site and splicing of an alternative first exon into an internal splice acceptor site located in the first exon of slL-lra (9) . The predicted proteins are thus identical except in their NH2 end, in which the first 21 amino acids of slL-lra are substituted by four amino acids in iclL-lra. Expression of transcripts coding for slL-lra and iclL-lra is differentially regulated (9) . slL-lra and iclL-la have similar capacity to inhibit IL-1 activity (10). The biological significance of iclL-lra is still unclear.
Here, we report the identification, cloning, and functional characterization of a new molecular form of iclL-lra generated by the expression of a new 63-bp exon located 2 kb downstream the first intracellular specific exon. We propose to refer to this new form of iclL-lra as iclL-lra type II (iclL-lralI).
Materials and Methods
Cells. Human circulating PMN, monocytes, and endothelial cells (EC) were obtained and cultured as described in previous reports (11) . Chronically infected U1 cells were cultured as described (12) . COS cells were cultivated in DMEM medium (Gibco, Glasgow, Scotland) with 10% FCS (Hyclone Laboratories, Logan, UT) and 8387 fibroblast cells in KPMI 1640 medium (Gibco) with 10% FCS (Hyclone). Human keratinocyte cultures were kindly provided by Prof. M. L. Tenchini (Dept. of Biology and Genetics for Medical Sciences, University of Milano, Milano, Italy).
Stimuli. Human recombinant (hr) IL-1B (3 x 107 U/rag) was from Domp~ (L 'Aquila, Italy). hrTNF-ol (6.6 x 107 U/mg) was from BASF (Knoll, Germany). LPS (LPS B from Escherichia coli 055:B5) was purchased from Difco Laboratories (Detroit, MI). PMA was from Sigma hrlblot and hrIb4 (5 x 107 U/mg) were from Immunex (Seattle, WA). hrlL-10 (107 U/mg) was from DNAX (Palo Alto, CA). Hrlb13 was from Sanofi Elf Bio Recherches (Labege, France). IgG for clinical use was from Sandoz (Basel, Switzerland) and was aggregated by heating at 63~ for 30 min.
Reverse Transcriptase PCR. Total RNA was extracted by the guanidinium thiocyanate method (13) . RT-PCK was performed as described (14) . Oligonucleotides were obtained from Duotech (Milano, haly). The sequences ofoligos used to selectively amplify iclblra were identical to those previously described (9) . In particular, we used oligos GM397 (indicated here as IRA 1) and GM368 (IRA 4). For iclIMraII amplification, we used IRA 4 and IRA 5 (5' CTGACTTGTATGAAGAAGGAGGTGG 3'), which specifically recognizes the extra exon described here included in the icIblraII sequence (Fig. 1) . The oligonucleotides for/$-actin amplification were 5' GCGCTCGTCGTCGACAACGG 3' and 5' GATAGACAA-CGTACATGGCTG 3'. Amplified products were run through a 1% ethidium bromide-stained agarose gel and transferred onto a nitrocellulose filter (Stratagene, La Jolla, CA); hybridization was carried out according to standard protocols (D), with a previously labeled oligonucleotide specific for icIblraII (5' GACTCAAAG-GAGACGATCTGCCG 3') (13) . Amplification products were subcloned (TA cloning system; InVitrogen, San Diego, CA) and sequenced by the chain termination method. Analysis of icIL-lraII sequence was performed with the Proexplore software package (Oxford Molecular Ltd., Oxford, UK).
PCR with Genomic DNA. Genomic DNA was extracted following standard protocols (13) from human circulating monocytes. 0.5 #g of genomic DNA was amplified at 94~ for 1 min, 60~ for 1 min, and 70~ for 4 min. We used IRA 1 (see above), IRA 9 (5 TTTGAGTCAGCATTGTCTTCA 3), IRA 7 (5 CTGACT-TGTATGAAGAAGGAGGTGG 3), and IRA 10, which is identical to B(BSI.1) (15) . Identification oflmmunoreactive IL1ra. A commercial ELISA assay (Amersham, Buckingamshire, UK), which identifies both sIL-lra and icIblra, was used. For Western blot analysis two polyclonal antisera (rabbit, generous gift from Dr. C. Dinarello, Tufts University, Boston, MA; and goat, Amersham) were used. COS cells lysates samples and supernatants were run on 12.5% SDS-PAGE and then blotted onto a nitrocellulose filter (Stratagene). Immunoreactire protein bands were revealed by a chemiluminescence-based procedure (ECL detection; Amersham) according to the manufacturer's instructions.
Expression of icILlra Products in COS
ILl Responses. Confluent EC cultivated in 96-well plates (Falcon Labware, Oxnard, CA) were incubated for 30 min with an amount of transfected COS cell lysate (see above) corresponding to 25-100 ng of recombinant Iblra (either icIL-lraI or icIL-lraII), as assessed by a specific ELISA assay (Amersham). As a control, an equal amount of COS lysate obtained from mock-transfected ceils was used in parallel. Next, 0.1-1 ng/ml human recombinant Ibl/~ was added to the cultures for 6 h. The detection of E-selectin expression was made with an ELISA assay on adherent EC with the anti-E-selectin mAb BB1C-E2 (courtesy of Dr. A. Gearing, British Biotechnology, Oxford, UK) as primary Ab and a rabbit anti-mouse Ig antiserum conjugated with horseradish peroxidase as a secondary Ab. Optical density quantification was determined with a spectrophotometer (Flow, Milano, Italy) at a 405-nm wavelength.
Chronically infected U1 cells (2 x 10 s cells/ml in 24-weU plates; Falcon) were stimulated with IblB (0.01-10 ng/ml) in the presence or absence of 100-fold excess of icIblraI or icIblralI or an equal amount of COS lysate obtained from mock-transfected cells. Cell culture supernatants were harvested 72 and 144 h after stimulation and tested for the presence of Mg + +-dependent RT activity as a parameter of virion production (12) .
Results

Identification of a New Isoform of iclL-Ira.
Specific oligonucleotide primers were designed (Fig. 1, IRA1 and IRA4) to amplify the entire coding sequence of icIL-lra ( Fig. 1) by RT-PCK. Amplified products from human polymorphonudear ceUs were subcloned and sequenced. In addition to the previously known sequence of icIL-lra, we isolated a number of clones whose sequences were identical to the published icIL-lra coding sequence, with the notable exception of an extra 63-bp sequence between nucleotides 132 and 133 of the iclL-lra sequence. Given the described exon-intron boundaries of icIL-lra (8) , the extra sequence is inserted between the first leaderless exon of iclL-lra and its second exon, which corresponds to the 3' half of the first exon of slL-lra (Fig. 1) . The predicted amino acid sequence is shown in Fig. 1 . The putative new protein (thereafter referred to as icIL-lraII) has the first three amino acids at the NH2 end in common with the classical icIL-lra (therefore referred to as iclL-lraI), followed by a new sequence of 21 amino acids. The rest of the two proteins are identical. The complete icILlraII consists of 180 amino acids. The most striking characteristic of the inserted extra sequence is the presence of seven glycine residues, six of which are consecutive. Glycine residues are flanked on both sides by glutamic acid residues. Computer analysis of iclL-lraII-specific sequence was performed, and a number of genes showed a similarity to the icIL-lraII specific exon (not shown). The overall hydrophilic pattern of icIL-lraII is similar to that of icIL-lraI, lacking a hydrophobic leader peptide at the NH2 terminus (not shown).
Genomic Organization of lL-lra Gene. The icIL-lraI first exon had been previously localized ,,o9.6 kb upstream of the slL-lra first exon (reference 8 and Fig. 2 ), but sequence information was available for a 6-kb region located immediately upstream of the slL-lra first exon (15, 16) . This intronic sequence did not contain our putative extra exon. We hypothesized, therefore, that the putative extra exon might be localized in the remaining 3.5-kb genomic sequence not yet available (15, 16) . We therefore designed the IRA 10 oligonucleotide, which is colinear with the most 5' sequence of Figure 1 . eDNA sequence and predicted protein sequence of iclL-lralI compared to classical iclLlra (iclL-lraI) and slblra. The upper part of the figure shows the eDNA and protein sequences specific for slLolra, iclblraI, and iclL-lralI. The lower part of the figure shows the sequence in common among the three forms of Iblra. For clarity, the eDNA sequence of iclL-lra starts from nucleotide 91 of the published 5' untranslated sequence, and only 6 bp of the 3' untranslated sequence are reported. The common IL-lra sequence starts with the internal acceptor site located in the first exon of slDlra, corresponding to nucleotide 133 of the complete iclL-lraI sequence and to nucleotide 88 of the complete sllclra sequence. The PCR primers (see text) are indicated with arrows. The asterisk indicates the stop codon. The sequence is available from EMBL/Gene Bank/DDBJ under accession number X84348. the known intronic sequence (16) , and IRA 1 oligonucleotide, whose sequence is contained within the first iclL-lra exon. The genomic 3.5-kb fragment was amplified, cloned, and sequenced. As expected, the corresponding 63-nucleotide sequence was found at a distance of 2.1 kb downstream relative to the first iclL-lraI exon and was flanked by the exonintron junction consensus AG and GT nucleotides. To further verify the exact localization of the extra exon, other oligonucleotides were constructed (IRA 9 and IRA 7; see Fig. 2 ), and the size of the amplified fragments was consistent with the indicated localization (data not shown).
Expression of iclL-ra in Different Cell
Types. To identify iclLlralI transcripts, RT-PCK analysis was performed with IRA 4 and IRA 5 oligonucleotides (Fig. 1) . As shown in Fig. 3 A, a signal specific for iclL-lralI is not present in quiescent (lane 1) or LPS-stimulated (lane 3) 8387 fibroblasts, but was dearly induced upon exposure to PMA (lane 2), TNF-cx (lane 4), and IL-lol (lane 5). In parallel experiments, these same stimuli were equally effective for the induction of the iclLlraI expression (data not shown and reference 17). When expression in monocytes was studied (Fig. 3 B) , a distinct band for iclL-lralI was evident after hybridization with a specific oligonucleotide and was induced by LPS treatment (lane 5).
In parallel experiments, IL-4, IL-10, IL-13, LPS, and aggregated IgG were equally effective in inducing iclL-lraI expression (data not shown and reference 14). Expression of iclL-lralI was also studied in polymorphonuclear cells, either unstimulated or exposed to several stimuli including IL-4, IL-10, IL-13, LPS, and aggregated IgG. A band was present after hybridization with a specific oligonucleotide and was not modified much by different stimuli (Fig. 3 C) . Under identical conditions, we had reported the induction of iclLlraI upon exposure of polymorphonuclear cells to IL-13 (14) . Finally, keratinocytes, which express iclL-lraI (9), showed high levels of iclL-lralI mRNA. The specificity of amplified products from PMA-treated fibroblasts and LPS-stimulated monocytes was confirmed by subcloning and sequencing (not shown). All in all, these results indicate that iclL-lralI is expressed in a variety of cell types, with a pattern of induction that is to some extent different from that of iclL-lraI and slL-lra.
Expression of Recombinant iclL-lralI and Biological
Activity. COS cells were transfected with the cDNA sequences coding for iclL-lralI or iclL-lraI, and cell lysates and supernatants were examined in Western blots. The rabbit polyclonal antisera used in these experiments recognized equally well iclL-lralI and iclL-lraI, which were found mostly in cell lysate (data not shown). Recombinant iclL-lraI migrated as a major 22-kD band, whereas iclL-lralI showed a mass of ~25 kD (Fig. 4) .
Recombinant iclL-lraI and iclL-lralI were examined for their ability to inhibit IL-l-induced E-selectin expression on endothelial cells. Lysates from mock-transfected COS cells did not significantly reduce IL-1 activity, iclL-lralI had no agonistic activity. As shown in Fig. 5 (representative of three experiments), recombinant iclL-lralI inhibited E-selectin induction in a dose-dependent fashion. The inhibitory activity oficlL-lralI was similar to that exerted by iclL-lraI expressed A New Isoform of the Interleukin 1 Receptor Antagonist under the same experimental conditions. Recombinant iclLlraI and iclL-lralI were also tested for their ability to inhibit IL-1-induced HIV expression in U1 cells. Induction of HIV expression from U1 cells was not observed at any tested concentration (up to 1/zg/ml) of iclL-lralI, iclL-lralI suppressed IL-13-dependent triggering of HIV expression in U1 cells (data not shown).
Discussion
In this report, we describe a new molecular form of ILlra, termed iclL-lralI, iclL-lralI is identical to iclL-lraI, except for an additional stretch of 21 amino acids located within the NH2-terminal portion of the molecule. This iclL-lralI sequence is encoded by a novel exon located within the 9.6-kb region between the first and second exon of iclL-lraI. Thus, by differential splicing, three isoforms of IL-lra are generated and their expression is, to some extent, differentially regulated in different cell types and/or in response to different stimuli.
iclL-lralI is biologically active, in that the molecule expressed in COS cells inhibit IL-1/3 activity with ef~ciency comparable to that oficlL-lraI. It has previously been reported that iclL-lraI and slL-lra have similar capacity to inhibit IL-1 (10) . The actual biological significance of the intracellular isoforms of IL-lra and of their differential expression remains unclear. They may represent reservoirs of IL-lra, to be released upon cell death or to inhibit putative intracellular actions of IL-1. The IL-1 system shows an extraordinary level of complexity, consisting of two agonists, two receptors (one of which is an inhibitor of IL-1 [2] [3] [4] ), and a receptor antagonist (of which at least three different molecular forms exist). Although the biological significance of the intracellular forms of IL-lra remains to be clearly established, our data indicate that two different forms of iclL-lra with different NH2 termini are generated by alternative splicing in response to selected external stimuli. The existence of multiple levels of control of IL-1 points to the requirement for a tight physiological control of the inflammatory potential of this cytokine.
